Recombinant interferon-gamma - Amoytop Biotech/BioGeneric Pharma

Drug Profile

Recombinant interferon-gamma - Amoytop Biotech/BioGeneric Pharma

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amoytop Biotech; BioGeneric Pharma
  • Developer Amoytop Biotech
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunostimulants; Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Unspecified

Most Recent Events

  • 06 Jan 2016 Clinical trials in Undefined indication in China (unspecified route)
  • 06 Aug 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top